Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01796262
Recruitment Status : Completed
First Posted : February 21, 2013
Last Update Posted : February 26, 2020
Sponsor:
Collaborator:
DMF srl (Dietetic Metabolic Food)
Information provided by (Responsible Party):
IRCCS Eugenio Medea

Brief Summary:
The purpose of this study is to determine whether docosahexaenoic acid (DHA) is effective in reducing Attention Deficit/Hyperactivity Disorder (ADHD) core symptoms in a clinical sample of children and adolescents with ADHD.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Dietary Supplement: docosahexaenoic acid Dietary Supplement: Wheat germ oil Phase 3

Detailed Description:

The primary objective of this study is to investigate the relative efficacy and tolerability of omega-3 fatty acid supplementation, more specifically docosahexaenoic acid (DHA), in reducing attention-deficit/hyperactivity disorder (ADHD) symptoms in children. The present study is going to determine whether DHA supplementation induces modifications in fatty acid blood level and to evaluate the correlation between this possible modification and behavioral, neuropsychological and functional indexes. The study is a randomised, placebo-controlled double-blind intervention trial providing within- and between-group comparisons over 6 months. At the start of the study, the patients will be randomized to active treatment with DHA in a dose of one capsules twice daily, corresponding to a daily dose of 500 mg DHA, or to placebo (identical capsules with fishy odor containing 500 mg wheat germ oil). A total of 50 patients will be included in the study which is conducted in the Child Psychiatry Unit of "E. Medea" Scientific Institute (in northern Italy). The study participants are recruited from among patients assessed and diagnosed at this clinic, aged 6 to 14 years, who met DSM-IV criteria for a diagnosis of ADHD of any subtype (see Eligibility Criteria for further details). The study will also recruit 20 typically developing children to provide a control group at the start of the research for comparison of fatty acid blood level and other outcome measures (healthy children will not be included in the supplementation phase).

Clinical assessment will be made were made at three visits at the site: at baseline (Visit 1), 4 months (Visit 2) and 6 months (Visit 3). At Visits 1-2-3, a blood sample will be taken for analysis of the blood fatty acid profile. At Visit 1, informed consent is signed, inclusion and exclusion criteria are assessed, and the investigators make a medical evaluation, including medical and psychiatric history, assessment of diagnosis and comorbidity through parent interview according to DSM-IV criteria (DAWBA). A number of other examinations and instruments will be used, including height and weight, pulse and blood pressure, a neuromotor examination and an assessment of the general level of functioning with clinical scales and questionnaires completed by parents (see Outcome Measure Section for more details); several neuropsychological tests and reading test will be performed by a developmental neuropsychologist. At Visits 1-2, changes in the concentration of oxygenated Hb and deoxygenated Hb in prefrontal cortex during a computerized visual working memory task will be assessed in a subset of patients (10 children from each group) with functional Near-Infrared Spectroscopy. Visit 2 will included the same examinations and instruments as Visit 1, with the exception of the reading test; Visit 3 will included all the same measures as Visit 1, with the exception of the fNIRS. Parents will return every month at the clinic to assess the compliance (defined as taking the prescribed dosage on more than 70% of the days in the interval), to be interviewed about current medical symptoms and any adverse events or side effects, and to get the supplementation dosage for the following month.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder
Study Start Date : June 2012
Actual Primary Completion Date : February 2015
Actual Study Completion Date : June 2015


Arm Intervention/treatment
Placebo Comparator: Wheat germ oil
Wheat germ oil 250 mg pearl b.i.d. for six months
Dietary Supplement: Wheat germ oil
Wheat germ oil 250 mg pearl b.i.d. for six months
Other Name: Wheat germ oil 250 mg pearl

Active Comparator: docosahexaenoic acid
DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
Dietary Supplement: docosahexaenoic acid
Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
Other Name: DHA Richoil (DMF srl)




Primary Outcome Measures :
  1. Change in ADHD RS-IV total score [ Time Frame: Baseline, month 4, and month 6 ]
    ADHD rating scale IV Parent Version-Investigator completed


Secondary Outcome Measures :
  1. Change in CPRS-R [ Time Frame: Baseline, month 4, and month 6 ]
    Conners Parent Rating Scale Revised

  2. Change in CGI-S [ Time Frame: Baseline, month 4, and month 6 ]
    Clinical Global Impression - Severity

  3. Change in C-GAS [ Time Frame: Baseline, month 4, and month 6 ]
    Children Global Assessment Scale

  4. Change in CHQ [ Time Frame: Baseline, month 4, and month 6 ]
    Child Health Questionnaire Total Score

  5. Change SDQ Total Score [ Time Frame: Baseline, month 4, and month 6 ]
    Strenght and Difficulties Questionnaires


Other Outcome Measures:
  1. Change in Functional Neuroimaging (functional Near-Infrared Spectroscopy) [ Time Frame: Baseline and month 4 ]
    Changes in the concentration of oxygenated Hb and deoxygenated Hb in prefrontal cortex during a computerized visual working memory task

  2. Change in Cognitive Measure (ANT) [ Time Frame: Baseline, month 4, and month 6 ]
    Amsterdam Neuropsychological Task

  3. Change in Fatty Acid blood level [ Time Frame: Baseline, month 4, and month 6 ]
    Fatty Acid blood level



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of ADHD based on DSM-IV criteria and confirmed with Development and Well-Being Assessment (DAWBA) interview
  • Comorbid disorder accepted: mood disorder, anxiety disorder, oppositional defiant disorder, conduct disorder, learning disorder
  • Total IQ equal or above 85
  • Aged from 6 to 14 years

Exclusion Criteria:

  • Autism, Schizophrenia or othe psychiatric disorder not included in inclusion criteria
  • associated neurologic, genetic, infectious or metabolic disorder, or a seizure disorder
  • present or past use of any psychoactive drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01796262


Locations
Layout table for location information
Italy
IRCCS Eugenio Medea
Bosisio Parini, Lecco, Italy, 23842
Sponsors and Collaborators
IRCCS Eugenio Medea
DMF srl (Dietetic Metabolic Food)
Investigators
Layout table for investigator information
Principal Investigator: Maria Nobile, MD, PhD IRCCS 'Eugenio Medea'
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: IRCCS Eugenio Medea
ClinicalTrials.gov Identifier: NCT01796262    
Other Study ID Numbers: EM-00-11
First Posted: February 21, 2013    Key Record Dates
Last Update Posted: February 26, 2020
Last Verified: August 2015
Keywords provided by IRCCS Eugenio Medea:
ADHD
DHA
neuropsychological task
fNIRS
Docosahexaenoic Acid
n-3 polyunsaturated fatty acid
cognition
behavior
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms